| Literature DB >> 31791115 |
Mudan Cai1, Inho Jung1, Huiyoung Kwon2, Eunbi Cho2, Jieun Jeon2, Jeanho Yun3,4, Young Choon Lee2,4, Dong Hyun Kim2,4, Jong Hoon Ryu1,5.
Abstract
Hippocampal synaptic dysfunction is a hallmark of Alzheimer's disease (AD). Many agents regulating hippocampal synaptic plasticity show an ameliorative effect on AD pathology, making them potential candidates for AD therapy. In the present study, we investigated spinosin as a regulating agent of synaptic plasticity in AD. Spinosin attenuated amyloid β (Aβ)-induced long-term potentiation (LTP) impairment, and improved plasmin activity and protein level in the hippocampi of 5XFAD mice, a transgenic AD mouse model. Moreover, the effect of spinosin on hippocampal LTP in 5XFAD mice was prevented by 6-aminocaproic acid, a plasmin inhibitor. These results suggest that spinosin improves synaptic function in the AD hippocampus by regulating plasmin activity.Entities:
Keywords: 5XFAD; Alzheimer’s disease; LTP; Plasmin; Spinosin
Year: 2020 PMID: 31791115 DOI: 10.4062/biomolther.2019.076
Source DB: PubMed Journal: Biomol Ther (Seoul) ISSN: 1976-9148 Impact factor: 4.634